Unknown

Dataset Information

0

A novel small-molecule activator of Sirtuin-1 induces autophagic cell death/mitophagy as a potential therapeutic strategy in glioblastoma.


ABSTRACT: Sirtuin-1 (SIRT1), the mammalian ortholog of yeast Sir2p, is well known to be a highly conserved NAD+-dependent protein deacetylase that has been emerging as a key cancer target. Autophagy, an evolutionarily conserved, multi-step lysosomal degradation process, has been implicated in cancer. Accumulating evidence has recently revealed that SIRT1 may act as a tumor suppressor in several types of cancer, and thus activating SIRT1 would represent a possible therapeutic strategy. Thus, in our study, we identified that SIRT1 was a key prognostic factor in brain cancer based upon The Cancer Genome Atlas and tissue microarray analyses. Subsequently, we screened a series of potential small-molecule activators of SIRT1 from Drugbank, and found the best candidate compound F0911-7667 (hereafter, named Comp 5), which showed a good deacetylase activity for SIRT1 rather than other Sirtuins. In addition, we demonstrated that Comp 5-induced autophagic cell death via the AMPK-mTOR-ULK complex in U87MG and T98G cells. Interestingly, Comp 5-induced mitophagy by the SIRT1-PINK1-Parkin pathway. Further iTRAQ-based proteomics analyses revealed that Comp 5 could induce autophagy/mitophagy by downregulating 14-3-3?, catalase, profilin-1, and HSP90?. Moreover, we showed that Comp 5 had a therapeutic potential on glioblastoma (GBM) and induced autophagy/mitophagy by activating SIRT1 in vivo. Together, these results demonstrate a novel small-molecule activator of SIRT1 that induces autophagic cell death/mitophagy in GBM cells, which would be utilized to exploit this compound as a leading drug for future cancer therapy.

SUBMITTER: Yao ZQ 

PROVIDER: S-EPMC6039470 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

A novel small-molecule activator of Sirtuin-1 induces autophagic cell death/mitophagy as a potential therapeutic strategy in glioblastoma.

Yao Zhi-Qiang ZQ   Zhang Xin X   Zhen Yongqi Y   He Xu-Ying XY   Zhao Shuangmei S   Li Xi-Feng XF   Yang Bo B   Gao Feng F   Guo Fu-You FY   Fu Leilei L   Liu Xian-Zhi XZ   Duan Chuan-Zhi CZ  

Cell death & disease 20180710 7


Sirtuin-1 (SIRT1), the mammalian ortholog of yeast Sir2p, is well known to be a highly conserved NAD<sup>+</sup>-dependent protein deacetylase that has been emerging as a key cancer target. Autophagy, an evolutionarily conserved, multi-step lysosomal degradation process, has been implicated in cancer. Accumulating evidence has recently revealed that SIRT1 may act as a tumor suppressor in several types of cancer, and thus activating SIRT1 would represent a possible therapeutic strategy. Thus, in  ...[more]

Similar Datasets

| S-EPMC5636988 | biostudies-literature
| S-EPMC4884978 | biostudies-literature
| S-EPMC10082834 | biostudies-literature
| S-EPMC7933777 | biostudies-literature
| S-EPMC5462963 | biostudies-literature
2024-01-18 | GSE253113 | GEO
2023-03-22 | GSE188535 | GEO
| S-EPMC3715566 | biostudies-literature
2023-03-22 | GSE188534 | GEO
2023-03-22 | GSE188533 | GEO